Summarized by Masters of Longevity from Longevity Technology.
Longevity biotech’s economic case: an analytical piece that examines a report modeling how slowing aging could create vast diffuse societal value and why market incentives may fail to capture it.
Key Takeaways
- Slowing aging to add ten years of US life expectancy could generate roughly $7.2 trillion in annual economic value, reflecting broad productivity and healthcare cost benefits rather than direct profits to firms.
- Commercial market revenue for gerotherapeutics is projected much smaller—around $330 billion annually—meaning most societal gains will not flow directly to drugmakers or investors.
- Because markets underprice diffuse, long-term prevention benefits, public policy or collective action will likely be necessary to capture the majority of longevity gains for society.
